title: The role of mometasone furoate aqueous nasal spray in the treatment of adenoidal hypertrophy in the pediatric age group: preliminary results of a prospective, randomized study.
abstract: OBJECTIVE
  We evaluated the efficacy of mometasone furoate aqueous nasal spray in decreasing adenoid size and reducing the severity of chronic nasal obstruction symptoms in children affected by adenoidal hypertrophy.
  
  
  METHODS
  Sixty children were recruited in a 2-stage, randomized, placebo-controlled trial. All patients complained of chronic nasal obstruction symptoms, and nasal endoscopy showed >75% choanal obstruction attributable to adenoid pads. In the first stage, 30 patients (group A) underwent mometasone treatment (50 microg per nostril per day) for 40 days, and 30 children (group B) received placebo. In the second stage, at the end of the first 40-day treatment period, patients in group A who showed subjective and objective clinical improvement were divided into 2 subgroups; group A1 (11 children) received topical intranasal steroid treatment on alternate days for the first 2 weeks per month, whereas group A2 (10 children) continued daily mometasone treatment for the first 2 weeks per month. After 3 months, all children were reassessed.
  
  
  RESULTS
  Fifty-seven children completed the study according to the protocol. After the first treatment period, the severity of symptoms and adenoid size decreased for 21 patients (77.7%) in group A. No improvement was observed in the placebo group. After 3 months of additional therapy, group A2 patients demonstrated a more-pronounced reduction in adenoid size compared with group A1 patients. No statistically significant change in symptoms was identified. Mometasone treatment was well tolerated by all patients.
  
  
  CONCLUSIONS
  Mometasone furoate aqueous nasal spray may be considered useful in decreasing adenoid pad size and the severity of symptoms related to adenoidal hypertrophy. Children with adenoidal hypertrophy that is not associated with tonsillar hypertrophy should be considered for intranasal mometasone treatment before surgery is planned.
authors.affiliation: Department of Pediatric Otorhinolaryngology, Spedali Civili, Brescia, Italy.
authors.forename: Marco
authors.initials: M
authors.lastname: Berlucchi
authors.forename: Daria
authors.initials: D
authors.lastname: Salsi
authors.forename: Luisa
authors.initials: L
authors.lastname: Valetti
authors.forename: Giovanni
authors.initials: G
authors.lastname: Parrinello
authors.forename: Piero
authors.initials: P
authors.lastname: Nicolai
mesh_terms: D000234:Adenoids / Q000187:drug effects* / Q000473:pathology*; D000281:Administration, Intranasal; D002675:Child, Preschool; D005260:Female; D006801:Humans; D006984:Hypertrophy; D008297:Male; D000068656:Mometasone Furoate; D011244:Pregnadienediols / Q000008:administration & dosage*; D011446:Prospective Studies
chemical_list: D011244:Pregnadienediols; D000068656:Mometasone Furoate